Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2
Current Issues in Molecular Biology,
Год журнала:
2025,
Номер
47(5), С. 296 - 296
Опубликована: Апрель 23, 2025
Nectin-2
and
Nectin-4
are
cell
adhesion
molecules
associated
with
the
progression
of
various
cancers.
The
main
goal
this
pilot
study
was
to
evaluate
expression
patterns
in
laryngeal
squamous
carcinoma
(LSCC).
A
retrospective
conducted
on
tissue
microarray
(TMA)
samples
derived
from
31
patients
who
underwent
total
laryngectomy.
findings
revealed
heterogenous
both
tumor
cells
surrounding
stroma,
being
significantly
higher
than
expression.
Specifically,
74%
cases
showed
weak
cytoplasmic
staining
for
Nectin-2,
while
41.93%
exhibited
strong
Nectin-4.
Both
expressions
were
more
pronounced
at
invasive
margins.
Although
no
significant
differences
observed
across
grades
(W
=
83.500;
z
−0.463;
p
0.658),
noted.
Well-differentiated
tumors
(Grade
1),
80.65%
cases,
predominantly
membranous
staining,
including
epithelial
mucosal
surface.
Conversely,
less-differentiated
2
3),
a
shift
toward
evident.
74.19%
Grade
100%
3
predominant
localization
This
transition
also
evident
normal
superficial
epithelium
malignant
tissue.
These
observations
suggest
that
alterations
subcellular
may
be
carcinogenesis
could
serve
as
potential
markers
assessment
precancerous
lesions
aggressiveness
tumors.
Язык: Английский
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: a systematic review and meta-analysis
Critical Reviews in Oncology/Hematology,
Год журнала:
2024,
Номер
204, С. 104527 - 104527
Опубликована: Окт. 10, 2024
Язык: Английский
Advancements in Clinical Research and Emerging Therapies for Triple-Negative Breast Cancer Treatment
European Journal of Pharmacology,
Год журнала:
2024,
Номер
unknown, С. 177202 - 177202
Опубликована: Дек. 1, 2024
Язык: Английский
Future investigative directions for novel therapeutic targets in head and neck cancer
Expert Review of Anticancer Therapy,
Год журнала:
2024,
Номер
24(11), С. 1067 - 1084
Опубликована: Окт. 16, 2024
Here
we
describe
novel
agents,
their
mechanism(s)
of
action,
preclinical
results,
and
ongoing
clinical
trials
in
HNSCC.
Язык: Английский
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study
Clinical Genitourinary Cancer,
Год журнала:
2024,
Номер
unknown, С. 102278 - 102278
Опубликована: Ноя. 1, 2024
Язык: Английский
Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy
Phytotherapy Research,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 17, 2024
ABSTRACT
Natural
compound‐derived
chemotherapies
remain
central
to
cancer
treatment,
however,
they
often
cause
off‐target
side
effects
that
negatively
impact
patients'
quality
of
life.
In
contrast,
antibody‐drug
conjugates
(ADCs)
combine
cytotoxic
payloads
with
antibodies
specifically
target
cells.
Most
approved
and
clinically
investigated
ADCs
utilize
naturally
derived
payloads,
while
those
conventional
synthetic
molecular
limited.
This
review
focuses
on
enhance
the
efficacy
by
linking
them
antibodies.
We
provide
an
overview
core
components
ADCs,
their
working
mechanisms,
FDA‐approved
featuring
such
as
calicheamicin,
camptothecin,
dolastatin
10,
maytansine,
pyrrolbenzodiazepine
(PBD),
immunotoxin
Pseudomonas
exotoxin
A.
also
explores
recent
clinical
advancements
aimed
at
broadening
therapeutic
potential
applicability
in
treating
heterogeneously
composed
tumors
use
beyond
oncology.
Additionally,
this
highlights
are
currently
being
but
have
not
yet
received
approval.
By
summarizing
current
landscape,
provides
insights
into
promising
avenues
for
exploration
contributes
refinement
treatment
protocols
improved
patient
outcomes.
Язык: Английский
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy
Pharmaceuticals,
Год журнала:
2024,
Номер
17(12), С. 1701 - 1701
Опубликована: Дек. 17, 2024
The
present
review
provides
a
detailed
and
comprehensive
discussion
on
antibody–drug
conjugates
(ADCs)
as
an
evolving
new
modality
in
the
current
therapeutic
landscape
of
malignant
diseases.
principle
concepts
targeted
delivery
highly
toxic
agents
forsaken
stand-alone
drugs
are
examined
detail,
along
with
biochemical
technological
tools
for
their
successful
implementation.
An
extensive
analysis
ADCs’
major
components
is
conducted
parallel
function
impact
stability,
efficacy,
safety,
resistance
profiles
immunoconjugates.
scope
article
covers
classes
currently
validated
natural
compounds
used
payloads,
emphasis
structural
mechanistic
features,
origin,
distribution.
Future
perspectives
design
thoroughly
explored,
addressing
inherent
or
emerging
challenges
limitations.
survey
also
overview
molecular
rationale
active
tumor
targeting
ADC-based
platforms,
exploring
cellular
biology
clinical
relevance
markers
“homing”
mechanism
both
hematological
solid
malignancies.
Язык: Английский